BRAIN Biotech AG. (8/22/24). "Press Release: BRAIN Biotech AG Launches the Innovative Technology Platform MetXtra Enabling Unique Enzyme Solutions". Zwingenberg.

	Organisation	BRAIN Biotech AG
	Group	BRAIN Biotech (Group)
	Organisation 2	Biocatalysts Ltd.
	Group	BRAIN Biotech (Group)
	Product	MetXtra™ technology platform
	Product 2	industrial enzyme
	Person	Pelzer, Alexander (BRAIN Biotech 202302 Head of RnD at Zwingenberg site)
	Person 2	Konle, Stephanie (BRAIN 202002– Managing Associate Corporate Communications before Weka Business Medien + Merck)

BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, is proud to present MetXtra™, a comprehensive technology platform that enables innovative solutions for biocatalysis. MetXtra™ was developed by BRAIN Biotech to pave the way towards novel enzyme solutions and to overcome the current limitations of industrial biocatalysis.
Create competitive advantage with MetXtra™ by intelligently combining nature, bioinformatics and AI

MetXtra™ combines natural diversity with state-of-the-art bioinformatics and artificial intelligence to provide superior enzymes with high efficacy. Unique enzymes can be identified in BRAIN Biotech’s proprietary database of unexplored, Nagoya-compliant, novel sequences resulting from the fusion of the metagenomic sequence databases of BRAIN Biotech AG and Biocatalysts Ltd. The discovery of enzymes is tailored to the desired application utilizing BRAIN Biotech´s broad sequence and structural bioinformatics and AI toolbox. Additionally, new enzymes outside the natural sequence space are designed via artificial intelligence.

Dr. Alexander Pelzer, Vice President and Head of Research and Development at BRAIN Biotech Zwingenberg, states: "MetXtra gives our customers access to a comprehensive database of previously undiscovered enzymes. The cutting-edge bioinformatics methods allow us to quickly and precisely identify the appropriate enzyme for their specific applications, giving them a significant competitive advantage."

Development and Manufacturing of novel Enzymes in the BRAIN Biotech Group

BRAIN Biotech offers the MetXtra™ technology platform to customers aiming to establish and optimize biocatalytic processes, develop novel enzyme solutions, and generate IP or FTO.

MetXtra™ is fully integrated into the enzyme development pipeline of the BRAIN Biotech Group. This provides excellent opportunities for enzyme engineering, access to industrial enzyme production strains and scale-up technologies. In this way, the Group enables enzyme solutions from discovery to commercial production.

More information about MetXtra (PDF) [ Flyer, pp3, geholt als APPENDIX via https://www.brain-biotech.com/content/files/publications/BRAIN_Biotech_MetXtra-Enzyme-solution.pdf ; ML ]

About BRAIN

BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).

Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Contact Media

Dr. Stephanie Konle
pr@brain-biotech.com
+49 6251 9331 70

Contact Investor Relations

Martina Schuster
ir@brain-biotech.com
+49 6251 9331 69

Record changed: 2024-09-12